-+ 0.00%
-+ 0.00%
-+ 0.00%

MEDICUS PHARMA RECEIVES FDA “STUDY MAY PROCEED” CLEARANCE FOR TEVERELIX® PHASE 2B STUDY IN ADVANCED PROSTATE CANCER PATIENTS WITH HIGH CARDIOVASCULAR RISK

Reuters·02/10/2026 12:30:00

Please log in to view news